JP2011523626A - 化学療法、放射線療法、酸化ストレス、および加齢を防御するための食事組成物ならびに方法 - Google Patents

化学療法、放射線療法、酸化ストレス、および加齢を防御するための食事組成物ならびに方法 Download PDF

Info

Publication number
JP2011523626A
JP2011523626A JP2011506488A JP2011506488A JP2011523626A JP 2011523626 A JP2011523626 A JP 2011523626A JP 2011506488 A JP2011506488 A JP 2011506488A JP 2011506488 A JP2011506488 A JP 2011506488A JP 2011523626 A JP2011523626 A JP 2011523626A
Authority
JP
Japan
Prior art keywords
chemotherapy
animal
human
cells
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011506488A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011523626A5 (enExample
Inventor
ロンゴ，ヴァルトル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stevens Center for Innovation of USC
Original Assignee
Stevens Center for Innovation of USC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stevens Center for Innovation of USC filed Critical Stevens Center for Innovation of USC
Publication of JP2011523626A publication Critical patent/JP2011523626A/ja
Publication of JP2011523626A5 publication Critical patent/JP2011523626A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
JP2011506488A 2008-04-24 2009-04-24 化学療法、放射線療法、酸化ストレス、および加齢を防御するための食事組成物ならびに方法 Pending JP2011523626A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4768008P 2008-04-24 2008-04-24
US61/047,680 2008-04-24
PCT/US2009/041736 WO2009132320A2 (en) 2008-04-24 2009-04-24 Dietary compositions and methods for protection against chemotherapy, radiotherapy, oxidative stress, and aging

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015105690A Division JP2015186480A (ja) 2008-04-24 2015-05-25 化学療法、放射線療法、酸化ストレス、および加齢を防御するための食事組成物ならびに方法

Publications (2)

Publication Number Publication Date
JP2011523626A true JP2011523626A (ja) 2011-08-18
JP2011523626A5 JP2011523626A5 (enExample) 2015-07-16

Family

ID=41217444

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011506488A Pending JP2011523626A (ja) 2008-04-24 2009-04-24 化学療法、放射線療法、酸化ストレス、および加齢を防御するための食事組成物ならびに方法
JP2015105690A Pending JP2015186480A (ja) 2008-04-24 2015-05-25 化学療法、放射線療法、酸化ストレス、および加齢を防御するための食事組成物ならびに方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015105690A Pending JP2015186480A (ja) 2008-04-24 2015-05-25 化学療法、放射線療法、酸化ストレス、および加齢を防御するための食事組成物ならびに方法

Country Status (5)

Country Link
EP (1) EP2285218B1 (enExample)
JP (2) JP2011523626A (enExample)
CA (2) CA3045883C (enExample)
ES (1) ES2800327T3 (enExample)
WO (1) WO2009132320A2 (enExample)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015133627A1 (ja) * 2014-03-07 2015-09-11 味の素株式会社 虚弱予防剤
JP2016509994A (ja) * 2013-02-12 2016-04-04 ユニバーシティ オブ サザン カリフォルニア 化学毒性および年齢関連性の病気から保護するための方法および食事制限
JP2017513460A (ja) * 2014-03-06 2017-06-01 ユニヴァーシティ オブ サザン カリフォルニアＵｎｉｖｅｒｓｉｔｙ ｏｆ Ｓｏｕｔｈｅｒｎ Ｃａｌｉｆｏｒｎｉａ 従来の化学療法剤の効力および実行可能性を増強し、かつ正常な細胞および組織におけるキナーゼの副作用を逆転させるための、キナーゼ阻害剤と併用した短期間絶食レジメンの使用
KR20180016380A (ko) * 2015-05-06 2018-02-14 유니버시티 오브 써던 캘리포니아 고혈압 및 지질 장애를 치료하기 위한 금식 모방 및 향상된 규정식
JP2022501321A (ja) * 2018-09-27 2022-01-06 ソシエテ・デ・プロデュイ・ネスレ・エス・アー インスリン抵抗性及び／又は糖尿病の予防のための、ヒスチジンとグリシンと他のアミノ酸の使用
JP2023544981A (ja) * 2020-09-23 2023-10-26 アミノヴィタ エセ．エレ． 癌の代謝療法

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2676664B1 (en) * 2011-02-17 2017-06-21 EA Pharma Co., Ltd. Potentiator of antitumor activity of chemotherapeutic agent
JP5752980B2 (ja) * 2011-04-04 2015-07-22 日本メジフィジックス株式会社 腎臓トランスポーターの輸送能を抑制するための組成物
US20230000888A1 (en) 2019-12-19 2023-01-05 Leibniz-Institut Für Alternsforschung - Fritz-Lipmann-Institut E.V. (Fli) Nad-precursors and dietary restriction for treating age related medical conditions

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63502273A (ja) * 1985-12-19 1988-09-01 サントル・ナショナル・ド・ラ・ルシエルシエ・シヤンテイフイツク・（セ・エ−ヌ・エ−ル・エス） メチオニンの欠乏したかつホモシスティンを補足された栄養用組成物
JPH0368514A (ja) * 1989-08-09 1991-03-25 Morishita Pharmaceut Co Ltd 癌用アミノ酸製剤
JPH04352720A (ja) * 1991-05-30 1992-12-07 Tanabe Seiyaku Co Ltd 癌患者用アミノ酸製剤
WO1993006834A1 (en) * 1991-10-07 1993-04-15 Otsuka Pharmaceutical Factory, Inc. Enteral preparation for cancer therapy

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5535049A (en) 1978-09-04 1980-03-11 Otsuka Pharmaceut Factory Inc Amino acid transfusion for cancerous patient
US4574085A (en) * 1981-05-15 1986-03-04 Baxter Travenol Laboratories, Inc. Method for using dialysis solution containing glycerol
US4981687A (en) * 1988-07-29 1991-01-01 University Of Florida Compositions and methods for achieving improved physiological response to exercise
FR2673812B1 (fr) * 1991-03-13 1994-04-01 Roussel Uclaf Nouvelles compositions destinees a etre utilisees en dietetique et en therapeutique et renfermant une combinaison particuliere de glucides et leurs applications.
JP3380287B2 (ja) * 1992-04-07 2003-02-24 麒麟麦酒株式会社 血中アルコール濃度上昇阻害飲料
US6338856B1 (en) * 1998-02-27 2002-01-15 Texas Tech University Seaweed supplement diet for enhancing immune response in mammals and poultry
JPH11332514A (ja) * 1998-05-22 1999-12-07 Nof Corp バランス栄養食品
US7115297B2 (en) * 2000-02-22 2006-10-03 Suzanne Jaffe Stillman Nutritionally fortified liquid composition with added value delivery systems/elements/additives
US7744930B2 (en) * 2002-11-22 2010-06-29 Shaklee Corporation Compositions, methods and kits for enhancing weight loss while inhibiting loss of lean body mass
GB0416493D0 (en) * 2004-07-23 2004-08-25 Pitsiladis Yannis P Hydrating composition
EP1731145A1 (en) * 2005-05-25 2006-12-13 Institut National De La Recherche Agronomique Use of glycerol for improving cardiac function
KR20100015922A (ko) * 2007-03-26 2010-02-12 히로후미 마쓰이 암 환자용 수액 제제

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63502273A (ja) * 1985-12-19 1988-09-01 サントル・ナショナル・ド・ラ・ルシエルシエ・シヤンテイフイツク・（セ・エ−ヌ・エ−ル・エス） メチオニンの欠乏したかつホモシスティンを補足された栄養用組成物
JPH0368514A (ja) * 1989-08-09 1991-03-25 Morishita Pharmaceut Co Ltd 癌用アミノ酸製剤
JPH04352720A (ja) * 1991-05-30 1992-12-07 Tanabe Seiyaku Co Ltd 癌患者用アミノ酸製剤
WO1993006834A1 (en) * 1991-10-07 1993-04-15 Otsuka Pharmaceutical Factory, Inc. Enteral preparation for cancer therapy

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
JPN6013054113; 癌の臨床 ４０（１０）, 1994, ｐｐ．１１１１-１１１９ *
JPN6013054114; 産科と婦人科 ５８（１０）, 1991, ｐｐ．１９５８-１９６４ *
JPN6013054115; 日本癌治療学会誌 ２８（６）, 1993, ｐｐ．８５２-８６３ *
JPN6013054116; 日本癌治療学会誌 ２０（６）, 1985, ｐｐ．１０９３-１０９７ *
JPN6013054117; 臨床外科 ５２（７）, 1997, ｐｐ．８９９-９０３ *

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020073473A (ja) * 2013-02-12 2020-05-14 ユニバーシティ オブ サザン カリフォルニア 化学毒性および年齢関連性の病気から保護するための方法および食事制限
JP2016509994A (ja) * 2013-02-12 2016-04-04 ユニバーシティ オブ サザン カリフォルニア 化学毒性および年齢関連性の病気から保護するための方法および食事制限
JP2017513460A (ja) * 2014-03-06 2017-06-01 ユニヴァーシティ オブ サザン カリフォルニアＵｎｉｖｅｒｓｉｔｙ ｏｆ Ｓｏｕｔｈｅｒｎ Ｃａｌｉｆｏｒｎｉａ 従来の化学療法剤の効力および実行可能性を増強し、かつ正常な細胞および組織におけるキナーゼの副作用を逆転させるための、キナーゼ阻害剤と併用した短期間絶食レジメンの使用
JP2021020926A (ja) * 2014-03-06 2021-02-18 ユニヴァーシティ オブ サザン カリフォルニアＵｎｉｖｅｒｓｉｔｙ ｏｆ Ｓｏｕｔｈｅｒｎ Ｃａｌｉｆｏｒｎｉａ 従来の化学療法剤の効力および実行可能性を増強し、かつ正常な細胞および組織におけるキナーゼの副作用を逆転させるための、キナーゼ阻害剤と併用した短期間絶食レジメンの使用
JP7038432B2 (ja) 2014-03-06 2022-03-18 ユニヴァーシティ オブ サザン カリフォルニア 従来の化学療法剤の効力および実行可能性を増強し、かつ正常な細胞および組織におけるキナーゼの副作用を逆転させるための、キナーゼ阻害剤と併用した短期間絶食レジメンの使用
WO2015133627A1 (ja) * 2014-03-07 2015-09-11 味の素株式会社 虚弱予防剤
JPWO2015133627A1 (ja) * 2014-03-07 2017-04-06 味の素株式会社 虚弱予防剤
KR20180016380A (ko) * 2015-05-06 2018-02-14 유니버시티 오브 써던 캘리포니아 고혈압 및 지질 장애를 치료하기 위한 금식 모방 및 향상된 규정식
JP2018520645A (ja) * 2015-05-06 2018-08-02 ユニヴァーシティ オブ サザン カリフォルニアＵｎｉｖｅｒｓｉｔｙ ｏｆ Ｓｏｕｔｈｅｒｎ Ｃａｌｉｆｏｒｎｉａ 高血圧および脂質障害を処置するための絶食模倣促進食（ｆａｓｔｉｎｇ ｍｉｍｉｃｋｉｎｇ ａｎｄ ｅｎｈａｎｃｉｎｇ ｄｉｅｔ）
JP2021078509A (ja) * 2015-05-06 2021-05-27 ユニヴァーシティ オブ サザン カリフォルニアＵｎｉｖｅｒｓｉｔｙ ｏｆ Ｓｏｕｔｈｅｒｎ Ｃａｌｉｆｏｒｎｉａ 高血圧および脂質障害を処置するための絶食模倣促進食（ｆａｓｔｉｎｇ ｍｉｍｉｃｋｉｎｇ ａｎｄ ｅｎｈａｎｃｉｎｇ ｄｉｅｔ）
KR102811762B1 (ko) 2015-05-06 2025-05-22 유니버시티 오브 써던 캘리포니아 상승된 콜레스테롤 수준 및/또는 상승된 ldl 수준의 감소용 금식 모방 규정식 조성물
JP2022501321A (ja) * 2018-09-27 2022-01-06 ソシエテ・デ・プロデュイ・ネスレ・エス・アー インスリン抵抗性及び／又は糖尿病の予防のための、ヒスチジンとグリシンと他のアミノ酸の使用
JP2023544981A (ja) * 2020-09-23 2023-10-26 アミノヴィタ エセ．エレ． 癌の代謝療法
JP7727286B2 (ja) 2020-09-23 2025-08-21 アミノヴィタ エセ．エレ． 癌の代謝療法

Also Published As

Publication number Publication date
CA3045883C (en) 2022-06-28
WO2009132320A3 (en) 2010-01-07
CA2722365A1 (en) 2009-10-29
EP2285218B1 (en) 2020-06-17
CA3045883A1 (en) 2009-10-29
CA2722365C (en) 2019-08-06
ES2800327T3 (es) 2020-12-29
EP2285218A4 (en) 2011-10-05
EP2285218A2 (en) 2011-02-23
JP2015186480A (ja) 2015-10-29
WO2009132320A2 (en) 2009-10-29

Similar Documents

Publication Publication Date Title
US8865646B2 (en) Dietary compositions and methods for protection against chemotherapy, radiotherapy, oxidative stress, and aging
JP2015186480A (ja) 化学療法、放射線療法、酸化ストレス、および加齢を防御するための食事組成物ならびに方法
Knowlton et al. Heart failure and mitochondrial dysfunction: the role of mitochondrial fission/fusion abnormalities and new therapeutic strategies
Yang et al. Melatonin attenuates chronic pain related myocardial ischemic susceptibility through inhibiting RIP3-MLKL/CaMKII dependent necroptosis
Circu et al. Redox biology of the intestine
Vaughan et al. Cancer cachexia: impact, mechanisms and emerging treatments
ES2822178T3 (es) Formulaciones dietéticas que promueven la regeneración de tejidos/órganos
Dai et al. Anti-inflammatory effects of newly synthesized α-galacto-oligosaccharides on dextran sulfate sodium-induced colitis in C57BL/6J mice
Igarashi et al. Effective metabolic targeting of human osteosarcoma cells in vitro and in orthotopic nude-mouse models with recombinant methioninase
EP4190173B1 (en) Metabolic cancer therapy
Vernieri et al. Cyclic fasting-mimicking diet in cancer treatment: Preclinical and clinical evidence
US20220313694A1 (en) Reduced caloric intake and anticancer agents for the treatment of cancer
Yu et al. Ivabradine improved left ventricular function and pressure overload-induced cardiomyocyte apoptosis in a transverse aortic constriction mouse model
Lam et al. Dietary modulation of mitochondrial DNA damage: implications in aging and associated diseases
BR112020009552A2 (pt) combinação farmacêutica de inibidor da via de sinalização do receptor de andrógeno e de inibidor de p38 para uso no tratamento de câncer de próstata e uso de um inibidor de p38 para restaurar a sensibilidade à adt
Zhao et al. Glycolytic inhibition with 3-bromopyruvate suppresses tumor growth and improves survival in a murine model of anaplastic thyroid cancer
Karlstaedt et al. Actionable metabolic pathways in heart failure and cancer—lessons from cancer cell metabolism
Koňaříková et al. Current progress in the therapeutic options for mitochondrial disorders
van den Berg et al. Dietary acid load and rapid progression to end-stage renal disease of diabetic nephropathy in Westernized South Asian people
Yang et al. Effects of long-term supplementation of blue-green algae on lipid metabolism in C57BL/6J mice
US20090203784A1 (en) Treatment regimen for n-myc, c-myc, and l-myc amplified and overexpressed tumors
Teixeira et al. Mitochondria-targeted ROS scavenger JP4-039 improves cardiac function in a post-myocardial infarction animal model and induces angiogenesis in vitro
Choi et al. Vitamins B6 and cancer
Ju et al. Metabolic-immune microenvironment crosstalk mediating ICI resistance in MASH-HCC
US20080200422A1 (en) Methods for reduction of adipose tissue mass

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120323

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130321

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131105

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140129

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140305

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140307

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141125

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150223

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150325

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150427

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20150525

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150804